AmerisourceBergen earned a whopping $60.1 billion final quarter, thanks partly to its distribution of government-owned Covid deal withments. Now it’s time to reinvest a few of that money.
The pharmaceutical distributor is plunking down $1.28 billion to acquire PharmaLex, a German life sciences company that boasts a variety of consulting and support services from clinical development to post-launch, the companies announced on Monday.
Whereas the deal likely received’t shut until March 2023, CEO Steven Collis is alprepared anticipating the expansion of the company’s European footprint. PharmaLex is predicated in Germany, however holds offices by way ofout Europe, Asia, and within the US, Australia and Brazil, acwireing to the company’s netweb site.
“AmerisourceBergen is committed to constructing on our leadership in specialty services by way of a continued focus on innovation and halfnerships, and by acquiring PharmaLex, we can further enhance our value proposition to pharmaceutical manufacturers, from emerging biotechs to global biopharmaceutical leaders,” Collis mentioned in a information release.
PharmaLex can be swallowed by AmerisourceBergen’s International Well beingcare Solutions segment. AmerisourceBergen was not immediately availin a position for an interview.
The company’s US revenue reached $53.4 billion final quarter, up 6% from the identical period final 12 months. The company has supported a handful of Covid deal withments, including Eli Lilly’s antiphysique bamlanivimab, Gilead’s antiviral Veklury, and Merck and Ridgeagain’s molnupiravir.
PharmaLex isn’t Collis’ only large purchase in recent years. Final June, AmerisourceBergen closed on a $6.275 billion deal for Walgreens Boots Alliance’s Alliance Well beingcare business. Later that 12 months, the company unveiled its new 429,000-square-foot global headquarters in Conshohocken, PA.